CORona Drug InTEractions database
Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
Tamim Ahsana, Abu Ashfaqur Sajib
Abstract
Respiratory transmission is the primary route of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 surface spike glycoprotein for entry into human cells. A recent study reported absent to low expression of ACE2 in a variety of human lung epithelial cell samples. Three bioprojects (PRJEB4337, PRJNA270632 and PRJNA280600) invariably found abundant expression of ACE1 (a homolog of ACE2 and also known as ACE) in human lungs compared to very low expression of ACE2. In fact, ACE1 has a wider and more abundant tissue distribution compared to ACE2. Although it is not obvious from the primary sequence alignment of ACE1 and ACE2, comparison of X-ray crystallographic structures show striking similarities in the regions of the peptidase domains (PD) of these proteins, which is known (for ACE2) to interact with the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Critical amino acids in ACE2 that mediate interaction with the viral spike protein are present and organized in the same order in the PD of ACE1. In silico analysis predicts comparable interaction of SARS-CoV-2 spike protein with ACE1 and ACE2. In addition, this study predicts from a list of 1263 already approved drugs that may interact with ACE2 and/or ACE1 and potentially interfere with the entry of SARS-CoV-2 inside the host cells.
Source: PMC
Related molecules
Related interactions
Target | Target affiliation | Drug | Type | Result |
---|---|---|---|---|
Target | Target affiliation | Drug | Type | Result |
Name | Synonyms | Genes | Origin |
---|---|---|---|
Name | Synonyms | Genes | Origin |
Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
---|---|---|---|---|---|
Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
Title | Authors | DOI | Source | Article type | Date |
---|---|---|---|---|---|
Title | Authors | DOI | Source | Article type | Date |
Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
---|---|---|---|---|---|---|
Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID. It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
- Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction
- Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target
- Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug
- Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication
- Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial